Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422175 · ClinicalTrials.gov registry record · Phase 1
Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312
A Phase 1 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT00422175 is a Phase 1 study that has completed, run by Novartis. The registered enrollment target is 63 participants.
The verdict
NCT00422175, a Phase 1 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, and effect of oral BAF312 on bodily functions as well as the body's absorption, distribution, metabolism, and excretion of BAF312 in healthy volunteers
Interventions
- DRUG BAF 312
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00422175
The ClinicalTrials.gov registry entry for NCT00422175 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BAF 312 is the first listed.
NCT00422175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00422175 about?
NCT00422175 is a clinical study titled "Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312". The purpose of this study is to assess the safety, tolerability, and effect of oral BAF312 on bodily functions as well as the body's absorption, distribution, metabolism, and excretion of BAF312 in healthy volunteers
What is the current status of trial NCT00422175?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2006-10. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00422175?
The interventions under investigation include: BAF 312 (DRUG).
Who is sponsoring clinical trial NCT00422175?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.